The Fas counterattack: Cancer as a site of immune privilege

Joe O'Connell; Michael W. Bennett; Gerald C. O'Sullivan; J. Kevin Collins; Fergus Shanahan

doi:10.1016/S0167-5699(98)01382-6

The Fas counterattack: Cancer as a site of immune privilege

Joe O'Connell
, Michael W. Bennett
, Gerald C. O'Sullivan
, J. Kevin Collins
, Fergus Shanahan

University College Cork

University College Cork

Research output: Contribution to journal › Review article › peer-review

Abstract

Resistance to apoptosis through the Fas receptor pathway coupled with expression of the Fas ligand might enable many cancers to deliver a pre- emptive strike or counterattack against the immune system. Therapeutic exploitation of this has exciting potential, but now seems more complex and hazardous than was first evident.

Original language	English
Pages (from-to)	46-52
Number of pages	7
Journal	Immunology Today
Volume	20
Issue number	1
DOIs	https://doi.org/10.1016/S0167-5699(98)01382-6
Publication status	Published - 1 Jan 1999

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/S0167-5699(98)01382-6

Cite this

@article{2ac6cf64ff174681abecb30541ed9543,

title = "The Fas counterattack: Cancer as a site of immune privilege",

abstract = "Resistance to apoptosis through the Fas receptor pathway coupled with expression of the Fas ligand might enable many cancers to deliver a pre- emptive strike or counterattack against the immune system. Therapeutic exploitation of this has exciting potential, but now seems more complex and hazardous than was first evident.",

author = "Joe O'Connell and Bennett, \{Michael W.\} and O'Sullivan, \{Gerald C.\} and Collins, \{J. Kevin\} and Fergus Shanahan",

year = "1999",

month = jan,

day = "1",

doi = "10.1016/S0167-5699(98)01382-6",

language = "English",

volume = "20",

pages = "46--52",

journal = "Immunology Today",

issn = "0167-5699",

publisher = "Elsevier Ltd",

number = "1",

}

TY - JOUR

T1 - The Fas counterattack

T2 - Cancer as a site of immune privilege

AU - O'Connell, Joe

AU - Bennett, Michael W.

AU - O'Sullivan, Gerald C.

AU - Collins, J. Kevin

AU - Shanahan, Fergus

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Resistance to apoptosis through the Fas receptor pathway coupled with expression of the Fas ligand might enable many cancers to deliver a pre- emptive strike or counterattack against the immune system. Therapeutic exploitation of this has exciting potential, but now seems more complex and hazardous than was first evident.

AB - Resistance to apoptosis through the Fas receptor pathway coupled with expression of the Fas ligand might enable many cancers to deliver a pre- emptive strike or counterattack against the immune system. Therapeutic exploitation of this has exciting potential, but now seems more complex and hazardous than was first evident.

UR - https://www.scopus.com/pages/publications/0033018370

U2 - 10.1016/S0167-5699(98)01382-6

DO - 10.1016/S0167-5699(98)01382-6

M3 - Review article

C2 - 10081230

AN - SCOPUS:0033018370

SN - 0167-5699

VL - 20

SP - 46

EP - 52

JO - Immunology Today

JF - Immunology Today

IS - 1

ER -

The Fas counterattack: Cancer as a site of immune privilege

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this